53 related articles for article (PubMed ID: 25416104)
1. Bioenergetic dysfunction and inflammation in Alzheimer's disease: a possible connection.
Wilkins HM; Carl SM; Greenlief AC; Festoff BW; Swerdlow RH
Front Aging Neurosci; 2014; 6():311. PubMed ID: 25426068
[TBL] [Abstract][Full Text] [Related]
2. Proteasome activation: An innovative promising approach for delaying aging and retarding age-related diseases.
Chondrogianni N; Voutetakis K; Kapetanou M; Delitsikou V; Papaevgeniou N; Sakellari M; Lefaki M; Filippopoulou K; Gonos ES
Ageing Res Rev; 2015 Sep; 23(Pt A):37-55. PubMed ID: 25540941
[TBL] [Abstract][Full Text] [Related]
3. Heat shock protein 70 in Alzheimer's disease.
Lu RC; Tan MS; Wang H; Xie AM; Yu JT; Tan L
Biomed Res Int; 2014; 2014():435203. PubMed ID: 25431764
[TBL] [Abstract][Full Text] [Related]
4. Functions of the proteasome on chromatin.
McCann TS; Tansey WP
Biomolecules; 2014 Nov; 4(4):1026-44. PubMed ID: 25422899
[TBL] [Abstract][Full Text] [Related]
5. Neuropathological changes in aging brain.
Xekardaki A; Kövari E; Gold G; Papadimitropoulou A; Giacobini E; Herrmann F; Giannakopoulos P; Bouras C
Adv Exp Med Biol; 2015; 821():11-7. PubMed ID: 25416106
[TBL] [Abstract][Full Text] [Related]
6. Dihydroquinazolines enhance 20S proteasome activity and induce degradation of α-synuclein, an intrinsically disordered protein associated with neurodegeneration.
Fiolek TJ; Magyar CL; Wall TJ; Davies SB; Campbell MV; Savich CJ; Tepe JJ; Mosey RA
Bioorg Med Chem Lett; 2021 Mar; 36():127821. PubMed ID: 33513387
[TBL] [Abstract][Full Text] [Related]
7. Proteasome Activation to Combat Proteotoxicity.
Jones CL; Tepe JJ
Molecules; 2019 Aug; 24(15):. PubMed ID: 31387243
[TBL] [Abstract][Full Text] [Related]
8. Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders.
Njomen E; Tepe JJ
J Med Chem; 2019 Jul; 62(14):6469-6481. PubMed ID: 30839208
[TBL] [Abstract][Full Text] [Related]
9. TCF11 at the crossroads of oxidative stress and the ubiquitin proteasome system.
Koch A; Steffen J; Krüger E
Cell Cycle; 2011 Apr; 10(8):1200-7. PubMed ID: 21412055
[TBL] [Abstract][Full Text] [Related]
10. The Keap1-Nrf2 system and diabetes mellitus.
Uruno A; Yagishita Y; Yamamoto M
Arch Biochem Biophys; 2015 Jan; 566():76-84. PubMed ID: 25528168
[TBL] [Abstract][Full Text] [Related]
11. Proteasome activation delays aging and protects against proteotoxicity in neurodegenerative disease.
Gonos E
Adv Exp Med Biol; 2015; 821():7. PubMed ID: 25416104
[No Abstract] [Full Text] [Related]
12. [The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein].
Daks AA; Melino D; Barlev NA
Tsitologiia; 2013; 55(10):673-87. PubMed ID: 25509121
[TBL] [Abstract][Full Text] [Related]
13. Linkage between the proteasome pathway and neurodegenerative diseases and aging.
Vigouroux S; Briand M; Briand Y
Mol Neurobiol; 2004 Oct; 30(2):201-21. PubMed ID: 15475627
[TBL] [Abstract][Full Text] [Related]
14. The amazing ubiquitin-proteasome system: structural components and implication in aging.
Tsakiri EN; Trougakos IP
Int Rev Cell Mol Biol; 2015; 314():171-237. PubMed ID: 25619718
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
